Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve

European Journal of Clinical Pharmacology

Volumn 62, Issue 10, 2006, Pages 855-861

  Niioka, Takenori ^a   Uno, Tsukasa ^b   Yasui Furukori, Norio ^b   Shimizu, Mikiko ^b   Sugawara, Kazunobu ^a   Tateishi, Tomonori ^b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

AUC; CYP2C19 genotype; Limit sampling; Phenotype; Rabeprazole

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2C19; FLUVOXAMINE; FLUVOXAMINE MALEATE; PLACEBO; RABEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ALGORITHMS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLARITHROMYCIN; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FLUVOXAMINE; HALF-LIFE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; REGRESSION ANALYSIS; SULFIDES; TIME FACTORS;

EID: 33749457934     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0184-1     Document Type: Article

References (38)

1. Morii M, Hamatani K, Takeguchi N (1995) The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase. Biochem Pharmacol 49:1729-1734
2. Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ (1997) Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:973-980
3. Cloud ML, Enas N, Humphries TJ, Bassion S (1998) Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43:993-1000
4. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL (2002) A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16:479-485
5. Mario FD, Dal Bo N, Aragona G, Moussa AM, Iori V, Cavestro GM, Pilotto A, Leandro G, Franceschi M, Rugge M, Franze A (2003) Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. J Gastroenterol Hepatol 18:783-786
6. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanabe S, Sato N (1999) Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 13:741-746
7. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181-202
8. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T (2001) Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11:341-348
9. Klotz U, Schwab M, Treiber G (2004) CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 95:2-8
10. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 24:270-276
11. Junghard O, Hassan-Alin M, Hasselgren G (2002) The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 58:453-458
12. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290-301
13. Howden CW, Metz DC, Hunt B, Vakily M, Kukulka M, Amer F, Samra N (2006) Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. Aliment Pharmacol Ther 23:975-984
14. Pais SA, Nathwani RA, Dhar V, Nowain A, Laine L (2006) Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Aliment Pharmacol Ther 23:1607-1613
15. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141-152
16. Figgitt DP, McClellan KJ (2000) Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 60:925-954
17. Uno K, Suginoshita Y, Kakimi K, Moriyasu F, Hirosaki M, Shirakawa T, Kishida T (2006) Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 61:309-314
18. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E (1999) Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 66:265-274
19. Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T (2005) Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59:302-309
20. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T (2006) Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol (in press)
21. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (2006) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
22. Uno T, Yasui-Furukori N, Shimizu M, Sugawara K, Tateishi T (2005) Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 824:238-243
23. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
24. Niioka T, Yasui-Furukori N, Uno T, Sugawara K, Kaneko S, Tateishi T (2006) Identification of the time-point to give a plasma lansoprazole concentration that adequately reflected area under the concentration-time curve. Ther Drug Monit 28:321-325
25. Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ (1999) Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 21:691-701
26. Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399-431
27. Swan SK, Hoyumpa AM, Merritt GJ (1999) The pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 13:11-17
28. Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M (2003) Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 15:27-33
29. Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T (2001) A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 16:238-723
30. Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M (2001) Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 15:1479-1484
31. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M (2001) Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 33:671-675
32. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 3:27-36
33. Chong E, Ensom MH (2003) Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23:460-471
34. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727
35. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58:143-154
36. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113
37. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
38. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937